{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": 1398
        },
        "variant_string_id": "LRRK2 R1398H"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that LRRK2 variants act via a toxic gain of function mechanism coupled with an increase in kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that LRRK2 variants, particularly those causing increased kinase activity, contribute to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses in vitro kinase assays to evaluate kinase activity, which directly models the disease mechanism of increased kinase activity.",
          "judgment": "Yes",
          "reasoning": "Kinase assays are appropriate for evaluating the impact of variants on kinase activity, which is central to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: The study includes wild-type LRRK2 as a control and multiple replicates for the kinase assays.\n\nStep 3c: Variant Controls: Known pathogenic variants p.G2385R and p.R1628P were used as positive controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: The paper describes using wild-type LRRK2 and performing experiments in triplicate.\n\nStep 3c: Variant Controls: The study used known pathogenic variants as controls, enhancing the reliability of the results."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Not evaluated",
          "judgment": "Not evaluated",
          "reasoning": "No information provided in the paper"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting"
      },
      "overall_conclusion": "The variant p.R1398H shows significantly lower kinase activity compared to wild-type LRRK2, supporting its protective function. The evidence is robust due to the inclusion of appropriate controls and statistical analyses."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "R",
          "position": 2385
        },
        "variant_string_id": "LRRK2 G2385R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that LRRK2 variants act via a toxic gain of function mechanism coupled with an increase in kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that LRRK2 variants, particularly those causing increased kinase activity, contribute to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses in vitro kinase assays to evaluate kinase activity, which directly models the disease mechanism of increased kinase activity.",
          "judgment": "Yes",
          "reasoning": "Kinase assays are appropriate for evaluating the impact of variants on kinase activity, which is central to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: The study includes wild-type LRRK2 as a control and multiple replicates for the kinase assays.\n\nStep 3c: Variant Controls: Known pathogenic variants p.G2385R and p.R1628P were used as positive controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: The paper describes using wild-type LRRK2 and performing experiments in triplicate.\n\nStep 3c: Variant Controls: The study used known pathogenic variants as controls, enhancing the reliability of the results."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Not evaluated",
          "judgment": "Not evaluated",
          "reasoning": "No information provided in the paper"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The variant p.G2385R shows significantly higher kinase activity compared to wild-type LRRK2, supporting its pathogenic role. The evidence is robust due to the inclusion of appropriate controls and statistical analyses."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "P",
          "position": 1628
        },
        "variant_string_id": "LRRK2 R1628P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that LRRK2 variants act via a toxic gain of function mechanism coupled with an increase in kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that LRRK2 variants, particularly those causing increased kinase activity, contribute to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses in vitro kinase assays to evaluate kinase activity, which directly models the disease mechanism of increased kinase activity.",
          "judgment": "Yes",
          "reasoning": "Kinase assays are appropriate for evaluating the impact of variants on kinase activity, which is central to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: The study includes wild-type LRRK2 as a control and multiple replicates for the kinase assays.\n\nStep 3c: Variant Controls: Known pathogenic variants p.G2385R and p.R1628P were used as positive controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: The paper describes using wild-type LRRK2 and performing experiments in triplicate.\n\nStep 3c: Variant Controls: The study used known pathogenic variants as controls, enhancing the reliability of the results."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Not evaluated",
          "judgment": "Not evaluated",
          "reasoning": "No information provided in the paper"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The variant p.R1628P shows significantly higher kinase activity compared to wild-type LRRK2, supporting its pathogenic role. The evidence is robust due to the inclusion of appropriate controls and statistical analyses."
    }
  ]
}